FINV vs. VRNA

Last updated Jun 3, 2026

FINV (FinVolution Group) and VRNA (Verona Pharma plc) are both stocks. FINV operates in Credit Services (Financial Services), while VRNA operates in Biotechnology (Healthcare). At a 0.09 correlation, their price movements are largely independent.

Performance

FINV vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in FinVolution Group (FINV) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

FINV

• 1D: -3.01%
• 1M: 2.58%
• YTD: 4.92%
• 6M: 11.30%
• 1Y: -34.75%
• 3Y*: 13.39%
• 5Y*: -3.61%
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

FINV vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
FINV FinVolution Group	4.92%	-20.07%	45.47%	4.39%	6.39%	89.23%	8.51%	-22.85%	-49.37%	-45.64%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-4.88%

Correlation

The correlation between FINV and VRNA is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.03
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.12
Correlation (All Time) Calculated using the full available price history since Nov 13, 2017	0.09

The correlation between FINV and VRNA shifts across timeframes, from -0.03 (1 year) to 0.13 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap FINV : $1.32B VRNA : $9.72B
EPS FINV : $8.34 VRNA : -$0.69
PS Ratio FINV : 0.10 VRNA : 57.97
PB Ratio FINV : 0.08 VRNA : 34.92
Total Revenue (TTM) FINV : $13.24B VRNA : $167.65M
Gross Profit (TTM) FINV : $10.21B VRNA : $159.52M
EBITDA (TTM) FINV : $2.61B VRNA : -$40.86M

Return for Risk

FINV vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FINV

FINV Risk / Return Rank: 16
FINV Sharpe Ratio Rank: 11
FINV Sortino Ratio Rank: 13
FINV Omega Ratio Rank: 14
FINV Calmar Ratio Rank: 18
FINV Martin Ratio Rank: 24

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FINV vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for FinVolution Group (FINV) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	FINV	VRNA	Difference
Sharpe ratio Return per unit of total volatility	-0.71	—	—
Sortino ratio Return per unit of downside risk	-0.87	—	—
Omega ratio Gain probability vs. loss probability	0.90	—	—
Calmar ratio Return relative to maximum drawdown	-0.61	—	—
Martin ratio Return relative to average drawdown	-0.84	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	FINV	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.71	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.07	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.08	—	—

Drawdowns

Drawdown Indicators

	FINV	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-89.64%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-56.42%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-56.42%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-70.54%	—	—
Current Drawdown Current decline from peak	-48.23%	—	—
Average Drawdown Average peak-to-trough decline	-53.71%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	40.72%	—	—

Volatility

Volatility by Period

	FINV	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.89%	—	—
Volatility (6M) Calculated over the trailing 6-month period	33.93%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	48.97%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	50.26%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.88%	—	—

Dividends

FINV vs. VRNA - Dividend Comparison

FINV's dividend yield for the trailing twelve months is around 5.93%, while VRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
FINV FinVolution Group	5.93%	5.30%	3.49%	4.39%	4.13%	3.45%	4.49%	7.17%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

FINV vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between FinVolution Group and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

FINV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported a gross profit of 2.43B and revenue of 3.19B. Therefore, the gross margin over that period was 76.3%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

FINV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported an operating income of 526.49M and revenue of 3.19B, resulting in an operating margin of 16.5%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

FINV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported a net income of 412.55M and revenue of 3.19B, resulting in a net margin of 12.9%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both FINV and VRNA in my portfolio?

FINV and VRNA have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.